Marc Tessier-Lavigne - 23 Nov 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
23 Nov 2022
Net transactions value
-$609,600
Form type
4
Filing time
28 Nov 2022, 18:30:02 UTC
Previous filing
03 Nov 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $609,600 -20,000 -1.1% $30.48 1,870,356 23 Nov 2022 Direct F1, F2, F3
holding DNLI Common Stock 78,848 23 Nov 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 1 F4
holding DNLI Common Stock 79,173 23 Nov 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 2 F5
holding DNLI Common Stock 78,848 23 Nov 2022 The Tessier-Lavigne/Hynes Irrevocable Trust 3 F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.15 to $31.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 5,986 unvested restricted stock units.
F4 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
F5 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
F6 The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.